Westlake (WLK) Reports Q2 Earnings: What Key Metrics Have to Say

Westlake Chemical (WLK) reported significantly weaker-than-expected Q2 2025 results, with revenue of $2.95 billion missing consensus by 2.84% and EPS coming in at a loss of -$0.09, vastly underperforming the $0.06 estimate and declining sharply from $2.40 year-over-year. The poor performance extended to key operational metrics, as both Net External Sales and EBITDA across its Performance & Essential Materials and Housing & Infrastructure Products segments widely missed analyst estimates and saw year-over-year declines. This substantial earnings and metric miss, coupled with the stock's recent underperformance against the S&P 500, has resulted in a Zacks Strong Sell rating.

Analysis

Westlake Chemical's second-quarter 2025 results reveal a significant deterioration in operational and financial performance, missing analyst expectations across the board. The company reported revenue of $2.95 billion, a 7.9% year-over-year decline and a 2.84% miss against consensus estimates. More concerning is the swing to a net loss, with an EPS of -$0.09, which represents a stark reversal from the $2.40 profit in the prior-year quarter and a substantial -250% negative surprise versus the expected profit of $0.06. This weakness was broad-based, with both primary segments underperforming. The Performance and Essential Materials segment saw sales fall 10.9% YoY to $1.79 billion, while its EBITDA of $73 million was less than half the $167.07 million projected by analysts. Similarly, the Housing and Infrastructure Products segment's sales declined 2.9% YoY to $1.16 billion, with its EBITDA of $203 million falling significantly short of the $264.6 million estimate. This widespread underperformance and severe margin compression, reflected in the stock's -3.1% return over the past month against the S&P 500's +1% gain, has culminated in a Zacks Rank #5 (Strong Sell) rating, signaling a deeply bearish outlook.

Key Decisions for Investors

• Given the substantial miss on both revenue and earnings and the sharp reversal to a net loss from a significant profit a year ago, investors should re-evaluate long positions and exercise extreme caution.
• The severe margin compression, evidenced by the dramatic EBITDA misses in both core segments, is a critical red flag; any potential entry should be deferred until there is clear evidence of stabilizing input costs and pricing power.
• With the stock already underperforming the broader market and now carrying a 'Strong Sell' rating, a bearish stance is warranted in the near term, as the results suggest fundamental headwinds are intensifying.